John C. Hunter

Chief Scientific Officer at SiteOne Therapeutics

John C Hunter joined SiteOne in September 2018 as Chief Scientific Officer with over 30 years of experience as a highly-accomplished pharmaceutical research and development executive, having held multiple senior leadership positions within the pharmaceutical industry from Parke-Davis to Syntex/Roche and then Schering-Plough/Merck. Dr Hunter brings a wealth of expertise in leading complex, inter-disciplinary, drug development teams towards the successful progression of novel therapeutics to improve human health. This work has contributed towards several marketed products across diverse therapeutic categories with many more molecules reaching various stages of clinical development. He is a pharmacologist by training and has a specific interest and expertise in neurodegenerative disease and the contribution of the sensory nervous system to acute and chronic pain. He has contributed more than 100 peer-reviewed publications with several additional reviews and book chapters and is a member of the International Association for the Study of Pain and Society for Neuroscience. He earned a B.Sc. with honors and Ph.D. in Pharmacology from the University of Glasgow, U.K. followed by a Post-Doctoral Fellowship in Neuroscience at the University of Cambridge, U.K.

Timeline

  • Chief Scientific Officer

    Current role